Tandem Capital Management Corp Unicycive Therapeutics, Inc. Transaction History
Tandem Capital Management Corp
- $169 Million
- Q4 2024
A detailed history of Tandem Capital Management Corp transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Tandem Capital Management Corp holds 15,500 shares of UNCY stock, worth $9,145. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,500
Previous 15,500
-0.0%
Holding current value
$9,145
Previous $6,000
100.0%
% of portfolio
0.01%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding UNCY
# of Institutions
32Shares Held
61.7MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$6.48 Million5.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT10.4MShares$6.13 Million0.41% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$5.9 Million1.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.97MShares$5.88 Million1.54% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3 Million0.53% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.88M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...